Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on AxoGen, Inc. (NASDAQ:AXGN) on July 30, 2026.
reiterateNASDAQ:AXGN
HC Wainwright & Co. Reiterates Buy Rating on AxoGen, Inc. (AXGN)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on AxoGen, Inc. (NASDAQ:AXGN) on July 30, 2026.
Market Context
AxoGen, Inc. operates in the Healthcare sector. The stock currently trades at $41.35 with a market capitalization of $1.4B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AxoGen, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for AxoGen, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 30, 2026 | Canaccord Genuity | Buy | N/A |
| Jul 30, 2026 | Citizens | Market Outperform | N/A |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 29, 2026 | Wells Fargo | Overweight | N/A |
| Apr 29, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View AXGN Stock Page
Frequently Asked Questions
What does a Buy rating mean for AXGN?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on AxoGen, Inc. (NASDAQ:AXGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AXGN forecast page.
